Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.99 USD | +0.02% |
|
+0.02% | +30.06% |
07-02 | SpringWorks Therapeutics, Inc.(NasdaqGS:SWTX) dropped from S&P Biotechnology Select Industry Index | CI |
07-02 | SpringWorks Therapeutics, Inc.(NasdaqGS:SWTX) dropped from S&P Global BMI Index | CI |
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|
Assets | ||||||||
Cash And Equivalents | 147M | 104M | 67.49M | 176M | 69.75M | |||
Short Term Investments | 361M | 270M | 525M | 303M | 238M | |||
Total Cash And Short Term Investments | 508M | 374M | 592M | 479M | 308M | |||
Accounts Receivable, Total | - | - | - | 5.93M | 46.24M | |||
Total Receivables | - | - | - | 5.93M | 46.24M | |||
Inventory | - | - | - | 3.1M | 10.21M | |||
Prepaid Expenses | 4.91M | 9.41M | 7.55M | 12.68M | 16.03M | |||
Total Current Assets | 513M | 383M | 600M | 501M | 380M | |||
Gross Property Plant And Equipment | 3.55M | 5.22M | 19.51M | 26.74M | 32.05M | |||
Accumulated Depreciation | -529K | -1.02M | -1.24M | -2.66M | -5.39M | |||
Net Property Plant And Equipment | 3.02M | 4.2M | 18.27M | 24.09M | 26.66M | |||
Long-term Investments | 57.21M | 62.11M | 8.99M | 185M | 158M | |||
Other Intangibles, Total | - | - | - | 11.2M | 15.56M | |||
Deferred Charges Long-Term | - | - | - | - | - | |||
Other Long-Term Assets, Total | 2.57M | 3.27M | 3.23M | 4.25M | 6.47M | |||
Total Assets | 576M | 452M | 630M | 726M | 587M | |||
Liabilities | ||||||||
Accounts Payable, Total | 1.35M | 3.43M | 8.01M | 7.4M | 12.25M | |||
Accrued Expenses, Total | 14.88M | 25.38M | 39.24M | 65.57M | 86.01M | |||
Current Portion of Leases | 1.38M | 1.16M | 483K | 1.06M | 1.73M | |||
Unearned Revenue Current, Total | - | - | 3.31M | 4.14M | - | |||
Other Current Liabilities | - | - | - | - | - | |||
Total Current Liabilities | 17.61M | 29.97M | 51.05M | 78.17M | 99.99M | |||
Long-Term Leases | 1.36M | 129K | 4.77M | 6M | 6.18M | |||
Unearned Revenue Non Current | - | - | 16.23M | 15.4M | - | |||
Other Non Current Liabilities | 164K | - | - | - | - | |||
Total Liabilities | 19.13M | 30.1M | 72.05M | 99.57M | 106M | |||
Preferred Stock Convertible | - | - | - | - | - | |||
Total Preferred Equity | - | - | - | - | - | |||
Common Stock, Total | 5K | 5K | 6K | 7K | 7K | |||
Additional Paid In Capital | 676M | 715M | 1.13B | 1.52B | 1.65B | |||
Retained Earnings | -119M | -293M | -570M | -895M | -1.15B | |||
Treasury Stock | - | - | -1.34M | -4.14M | -12.58M | |||
Comprehensive Income and Other | 41K | -312K | -767K | 1.19M | 304K | |||
Total Common Equity | 557M | 422M | 558M | 626M | 481M | |||
Total Equity | 557M | 422M | 558M | 626M | 481M | |||
Total Liabilities And Equity | 576M | 452M | 630M | 726M | 587M | |||
Supplemental Items | ||||||||
ECS Total Shares Outstanding on Filing Date | 48.29M | 48.87M | 62.28M | 73.68M | 74.92M | |||
ECS Total Common Shares Outstanding | 48.13M | 48.78M | 62.2M | 73.38M | 74.39M | |||
Book Value / Share | 11.57 | 8.66 | 8.97 | 8.53 | 6.47 | |||
Tangible Book Value | 557M | 422M | 558M | 615M | 466M | |||
Tangible Book Value Per Share | 11.57 | 8.66 | 8.97 | 8.38 | 6.26 | |||
Total Debt | 2.73M | 1.29M | 5.25M | 7.06M | 7.91M | |||
Net Debt | -559M | -431M | -592M | -656M | -454M | |||
Debt Equivalent Oper. Leases | 12.28M | 12.33M | 11.74M | 20.15M | 22.78M | |||
Equity Method Investments, Total | 3.87M | 2.88M | 4.19M | 1.96M | 4.19M | |||
Account Code - Inventory Valuation | 3 | 3 | 3 | 3 | 5 | |||
Machinery, Total | 254K | 517K | 805K | 3.26M | 5.93M | |||
Full Time Employees | 78 | 176 | 227 | 305 | 368 |
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition